A Phase 4 interventional study of placebo and ibuprofen Formulation 1 in Pain, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Pain by Pfizer — none open to participants now, none under way, none of them phase 3. Pain · Pfizer.
Among the 74 studies in Pain by Pfizer, this one is the 34th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2008, is one of 7 in phase 4, and was the 29th registered.
10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →None of the 74 studies in Pain by Pfizer is open now. The open studies under Pain, anywhere →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 202 across the 71 interventional studies, 86 across the 3 observational. Of the 72 that completed or were terminated, 34 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 74 studies in Pain by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study of healthy volunteers to compare how quickly different ibuprofen products relieve dental pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusions criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: ibuprofen Formulation 1
Drug: ibuprofen Formulation 2
2 placebo gels capsules delivered as a single dose.
2 marketed ibuprofen gels
2 marketed ibuprofen gels
Time to Meaningful Pain Relief
Subjects evaluated the time to "First Perceptible" Relief by depressing a stopwatch at the moment they first began to experience "perceptible" relief and the time to "Meaningful" Relief by depressing a second stopwatch at the moment they first began to experience "meaningful" relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.
Time frame: 0-6 hours
Pain Intensity Difference (PID) Scores at Each Individual Time Points
PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.
Time frame: 0-6 hours
Pain Relief (PR) Scores at Individual Time Points
Response to the question "How much pain do you have from your starting pain?" was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.
Time frame: 0-6 hours
Time-weighted Sum of Pain Relief + Pain Intensity Difference (SPRID) From 0-2 Hours and 0-6 Hours
SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).
Time frame: 0-2 and 0-6 hours
Pain Relief Combined With Pain Intensity Difference (PRID) Scores at Individual Time Points
PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).
Time frame: 0-6 hours
Time-weighted Sum of Pain Intensity Difference (SPID) From 0-2 Hours and 0-6 Hours
SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).
Time frame: 0-2 and 0-6 hours
Time-weighted Sum of Pain Relief Scores (TOTPAR) From 0-2 Hours and 0-6 Hours
TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)
Time frame: 0-2 and 0-6 hours
Time to First Perceptible Relief
The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.
Time frame: 0-6 hours
Patients were recruited in the United States from August 2008 to October 2008.
| Milestone | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| Started | 33 | 88 | 90 |
| Completed | 32 | 88 | 90 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Subjects evaluated the time to "First Perceptible" Relief by depressing a stopwatch at the moment they first began to experience "perceptible" relief and the time to "Meaningful" Relief by depressing a second stopwatch at the moment they first began to experience "meaningful" relief. These times were recorded up to 6 hrs after dosing. Range: up to 6 hrs, a lower number is better.
| minutes | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| Time to Meaningful Pain Relief | — | 45.4 (41.5 to 53.5) | 63.6 (58.6 to 84.0) |
PID is based on the 4-point categorical pain severity score ranging from 0 (none) to 3 (severe), this value was derived by subtracting the score at each post-dosing time point from the baseline score, so that a higher positive value is indicative of greater improvement.
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 15 minutes | 0.1 ± 0.4 | 0.2 ± 0.5 | 0.1 ± 0.3 |
| 30 minutes | 0.2 ± 0.5 | 0.8 ± 0.8 | 0.5 ± 0.6 |
| 45 minutes | 0.3 ± 0.7 | 1.3 ± 0.8 | 0.9 ± 0.7 |
| 60 minutes | 0.3 ± 0.7 | 1.6 ± 0.9 | 1.2 ± 0.8 |
| 90 minutes | 0.2 ± 0.8 | 1.8 ± 0.9 | 1.5 ± 0.8 |
| 120 minutes | 0.2 ± 0.8 | 1.8 ± 0.9 | 1.7 ± 0.8 |
| 180 minutes | 0.3 ± 1.0 | 1.7 ± 1.0 | 1.7 ± 0.9 |
| 240 minutes | 0.4 ± 1.2 | 1.5 ± 1.0 | 1.5 ± 0.9 |
| 300 minutes | 0.2 ± 1.0 | 1.4 ± 1.0 | 1.4 ± 1.0 |
| 360 minutes | 0.2 ± 1.0 | 1.2 ± 1.0 | 1.3 ± 0.9 |
Response to the question "How much pain do you have from your starting pain?" was recorded on a 5-point categorical pain relief scale (None (0), A Little (1), Some (2), A Lot (3) or Complete (4)) at designated time points after study medication was taken.
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 15 minutes | 0.2 ± 0.5 | 0.5 ± 0.8 | 0.3 ± 0.6 |
| 30 minutes | 0.6 ± 0.8 | 1.6 ± 1.1 | 1.0 ± 0.9 |
| 45 minutes | 0.8 ± 1.0 | 2.4 ± 1.1 | 1.7 ± 1.1 |
| 60 minutes | 0.9 ± 1.1 | 2.9 ± 1.0 | 2.1 ± 1.1 |
| 90 minutes | 0.8 ± 1.1 | 3.2 ± 1.0 | 2.7 ± 1.0 |
| 120 minutes | 0.8 ± 1.2 | 3.2 ± 1.0 | 2.9 ± 1.0 |
| 180 minutes | 1.0 ± 1.4 | 3.0 ± 1.1 | 2.9 ± 1.1 |
| 240 minutes | 1.1 ± 1.6 | 2.7 ± 1.2 | 2.7 ± 1.2 |
| 300 minutes | 0.8 ± 1.2 | 2.5 ± 1.4 | 2.6 ± 1.3 |
| 360 minutes | 0.8 ± 1.3 | 2.2 ± 1.3 | 2.6 ± 1.3 |
SPRID is a derived endpoint from the pain relief and pain intensity difference scores from 0-2 hours and 0-6 hours. PRID=PID+Pain Relief Score. SPRID-02 range: -2 (worst) to 14 (best); SPRID 06 range: -6 (worst) to 42 (best).
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 0-2 hours | 1.8 ± 2.9 | 7.8 ± 2.9 | 6.3 ± 2.6 |
| 0-6 hours | 6.5 ± 11.9 | 24.0 ± 10.1 | 23.0 ± 9.5 |
PRID (PRID=PID+PR) is a derived endpoint from the pain relief and pain intensity difference scores at each time point. Range: -1 (worst) to 7 (best).
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 15 minutes | 0.3 ± 0.8 | 0.7 ± 1.2 | 0.4 ± 0.9 |
| 30 minutes | 0.8 ± 1.2 | 2.4 ± 1.8 | 1.4 ± 1.5 |
| 45 minutes | 1.1 ± 1.6 | 3.6 ± 1.8 | 2.5 ± 1.7 |
| 60 minutes | 1.2 ± 1.8 | 4.5 ± 1.8 | 3.3 ± 1.7 |
| 90 minutes | 1.0 ± 1.9 | 5.0 ± 1.7 | 4.2 ± 1.7 |
| 120 minutes | 1.0 ± 2.0 | 5.0 ± 1.8 | 4.6 ± 1.7 |
| 180 minutes | 1.2 ± 2.4 | 4.7 ± 2.0 | 4.6 ± 1.8 |
| 240 minutes | 1.5 ± 2.7 | 4.2 ± 2.1 | 4.2 ± 2.0 |
| 300 minutes | 1.0 ± 2.1 | 3.9 ± 2.3 | 4.0 ± 2.2 |
| 360 minutes | 1.0 ± 2.2 | 3.4 ± 2.3 | 3.9 ± 2.1 |
SPID is a derived endpoint from the pain intensity difference scores from 0-2 hours and 0-6 hours. Range: -2 (worst) to 6 (best); -6 (worst) to 18 (best).
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 0-2 hours | 0.4 ± 1.2 | 2.8 ± 1.4 | 2.2 ± 1.1 |
| 0-6 hours | 1.4 ± 5.2 | 8.6 ± 4.8 | 8.1 ± 4.2 |
TOTPAR is a derived endpoint from the pain relief scores from 0-2 hours and 0-6 hours. Range: 0 (worst) - 8 (best); 0 (worst) - 24 (best)
| units on scale | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| 0-2 hours | 1.4 ± 1.8 | 5.0 ± 1.7 | 4.1 ± 1.6 |
| 0-6 hours | 5.1 ± 7.1 | 15.4 ± 5.7 | 14.9 ± 5.8 |
The elapsed time from dosing until the patient indicated first perceptible relief, provided the subject also indicated achieving meaningful relief.
| minutes | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| Time to First Perceptible Relief | — | 23.7 (20.6 to 26.6) | 28.6 (25.9 to 31.5) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/33 (0%) | 13/33 (39.4%) |
| Ibuprofen Formulation 1 | — | 0/88 (0%) | 2/88 (2.3%) |
| Ibuprofen Formulation 2 | — | 0/90 (0%) | 7/90 (7.8%) |
| Event | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/33 | 1/88 | 2/90 |
| DizzinessNervous system disorders | 3/33 | 0/88 | 1/90 |
| VomitingGastrointestinal disorders | 2/33 | 1/88 | 1/90 |
| FatigueGeneral disorders | 1/33 | 0/88 | 0/90 |
| HeadacheNervous system disorders | 1/33 | 0/88 | 1/90 |
| SyncopeNervous system disorders | 1/33 | 0/88 | 0/90 |
| Hot flushVascular disorders | 1/33 | 0/88 | 0/90 |
| Dry socketInfections and infestations | 0/33 | 0/88 | 1/90 |
| Procedural site reactionInjury, poisoning and procedural complications | 0/33 | 0/88 | 1/90 |
| Age Continuous(years) | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 | Total |
|---|---|---|---|---|
| Mean | 18.8 ± 2.7 | 18.5 ± 2.5 | 19.0 ± 3.0 | 18.8 ± 2.7 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen Formulation 1 | Ibuprofen Formulation 2 | Total |
|---|---|---|---|---|
| Female | 16 | 43 | 45 | 104 |
| Male | 17 | 45 | 45 | 107 |
The record gives a start of Aug 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wyeth is now a wholly owned subsidiary of Pfizer →